1062 related articles for article (PubMed ID: 33920789)
1. MicroRNAs and Long Noncoding RNAs as Novel Therapeutic Targets in Estrogen Receptor-Positive Breast and Ovarian Cancers.
Barwal TS; Sharma U; Bazala S; Singh I; Jain M; Prakash H; Shekhar S; Sandberg EN; Bishayee A; Jain A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920789
[TBL] [Abstract][Full Text] [Related]
2. miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers.
Panoutsopoulou K; Avgeris M; Scorilas A
Expert Rev Mol Diagn; 2018 Nov; 18(11):963-979. PubMed ID: 30338716
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data.
Xiao B; Zhang W; Chen L; Hang J; Wang L; Zhang R; Liao Y; Chen J; Ma Q; Sun Z; Li L
Gene; 2018 Jun; 658():28-35. PubMed ID: 29518546
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
5. Noncoding RNAs in breast cancer.
Lo PK; Wolfson B; Zhou X; Duru N; Gernapudi R; Zhou Q
Brief Funct Genomics; 2016 May; 15(3):200-21. PubMed ID: 26685283
[TBL] [Abstract][Full Text] [Related]
6. Interplay Between Long Noncoding RNAs and MicroRNAs in Cancer.
Russo F; Fiscon G; Conte F; Rizzo M; Paci P; Pellegrini M
Methods Mol Biol; 2018; 1819():75-92. PubMed ID: 30421400
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA and LncRNA Expression Profiles in Human Estrogen Receptor Positive Breast Cancer.
Shao X; Huang P; Shi L; Lei L; Cao W; Chen Z; Wang X; Zheng Y
Clin Lab; 2019 Jan; 65(1):. PubMed ID: 30775882
[TBL] [Abstract][Full Text] [Related]
8. Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.
Ingle JN; Xie F; Ellis MJ; Goss PE; Shepherd LE; Chapman JW; Chen BE; Kubo M; Furukawa Y; Momozawa Y; Stearns V; Pritchard KI; Barman P; Carlson EE; Goetz MP; Weinshilboum RM; Kalari KR; Wang L
Cancer Res; 2016 Dec; 76(23):7012-7023. PubMed ID: 27758888
[TBL] [Abstract][Full Text] [Related]
9. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1.
Shibahara Y; Miki Y; Onodera Y; Hata S; Chan MS; Yiu CC; Loo TY; Nakamura Y; Akahira J; Ishida T; Abe K; Hirakawa H; Chow LW; Suzuki T; Ouchi N; Sasano H
J Pathol; 2012 Jul; 227(3):357-66. PubMed ID: 22407818
[TBL] [Abstract][Full Text] [Related]
10.
Fang Z; Wang Y; Wang Z; Xu M; Ren S; Yang D; Hong M; Xie W
Cancer Res; 2020 Oct; 80(20):4399-4413. PubMed ID: 32826278
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies.
Manna PR; Molehin D; Ahmed AU
Prog Mol Biol Transl Sci; 2016; 144():487-537. PubMed ID: 27865465
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
14. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
Hanamura T; Hayashi SI
Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
[TBL] [Abstract][Full Text] [Related]
15. LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack.
Venkatesh J; Wasson MD; Brown JM; Fernando W; Marcato P
Cancer Lett; 2021 Jul; 509():81-88. PubMed ID: 33848519
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding NR2F1-AS1 is associated with tumor recurrence in estrogen receptor-positive breast cancers.
Sanchez Calle A; Yamamoto T; Kawamura Y; Hironaka-Mitsuhashi A; Ono M; Tsuda H; Shimomura A; Tamura K; Takeshita F; Ochiya T; Yamamoto Y
Mol Oncol; 2020 Sep; 14(9):2271-2287. PubMed ID: 32392629
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
19. Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma.
Lim LJ; Wong SYS; Huang F; Lim S; Chong SS; Ooi LL; Kon OL; Lee CG
Cancer Res; 2019 Oct; 79(20):5131-5139. PubMed ID: 31337653
[TBL] [Abstract][Full Text] [Related]
20. Non-coding RNAs: long non-coding RNAs and microRNAs in endocrine-related cancers.
Klinge CM
Endocr Relat Cancer; 2018 Apr; 25(4):R259-R282. PubMed ID: 29440232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
